BioSpace News Archive

NOWDiagnostics, Inc. announced today that it has filed for expanded Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) of the ADEXUSDx® COVID-19 antibody test for point-of-care (POC)/CLIA waived testing. A prospective clinical trial of the ADEXUSDx® COVID-19 Antibody Test performed across three

Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use free flex ® Bags Acetaminophen is an option for multimodal pain management in the perioperative period.

New executive position will lead clinical team and oversee execution of remote delivery of industry-leading cancer support services

Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo’s Decision Support Solutions Through Concert’s Network of Laboratories and Health Plans

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing as

New comprehensive book and digital resources from the American Heart Association; made possible by a gift from Pete and Brandy Nordstrom

Genome Biologics UG, Frankfurt, Germany, today announced that they have entered into a research collaboration with AstraZeneca related to screening of proteins of the human secretome able to drive cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxicity (CT).

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it will host a conference call at 11:00 AM, Eastern Time on Wednesday, December 16, 2020,

- 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU - Multiple Global Phase 2/3 Trials to Begin Early 2021

Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. With these investments, Tempus has now raised around $1.05 billion. The